Literature DB >> 8382237

Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade.

M J Camargo1, N von Lutterotti, W G Campbell, M S Pecker, G D James, P B Timmermans, J H Laragh.   

Abstract

OBJECTIVE: To study the effects of renin-angiotensin system blockade by a novel non-peptide angiotensin II receptor antagonist, losartan, on development of hypertension and acceleration of end-organ damage in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). DESIGN AND METHODS: One hundred and eighty-one male SHRSP were fed a 4% sodium diet from 6 to 18 weeks of age. Seventy-eight SHRSP were treated orally with losartan, 30 mg/kg per day. One hundred and three rats constituted untreated controls. Blood pressure, plasma renin activity (PRA), renal function and end-organ damage were monitored during the transition to malignant hypertension.
RESULTS: Losartan prevented a blood pressure rise during the first 4 weeks of salt loading. Thereafter, blood pressure rose slowly in losartan-treated rats; however, at each time-point studied blood pressure was significantly lower in losartan-treated rats than in control rats. Losartan treatment increased PRA during the first 4 weeks, but this effect was not sustained. Thereafter, PRA decreased to control (week 0) levels. In contrast, 2 weeks after high-sodium feeding started, untreated SHRSP failed to suppress PRA appropriately; thereafter, PRA rose significantly. Losartan affected renal pathophysiology by blunting the decline in glomerular filtration rate, controlling proteinuria and preventing or delaying the appearance of malignant nephrosclerosis. Losartan treatment significantly increased survival and completely prevented cerebrovascular infarcts.
CONCLUSIONS: The results indicate that angiotensin II blockade markedly reduces both hypertension and end-organ damage in chronically salt-loaded SHRSP and that the renin-angiotensin system may play an important role in the development of hypertensive cardiovascular disease in SHRSP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382237     DOI: 10.1097/00004872-199301000-00006

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.

Authors:  V Y Wong; N J Laping; A H Nelson; L C Contino; B A Olson; E Gygielko; W G Campbell; F Barone; D P Brooks
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

3.  Chronic vagal nerve stimulation prevents high-salt diet-induced endothelial dysfunction and aortic stiffening in stroke-prone spontaneously hypertensive rats.

Authors:  Mark W Chapleau; Diane L Rotella; John J Reho; Kamal Rahmouni; Harald M Stauss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-20       Impact factor: 4.733

4.  Angiotensin II type 1 receptors may not influence response of spinal autonomic neurons to axonal damage.

Authors:  Hui Tang; Jaroslav Pavel; Juan M Saavedra; Stephen Brimijoin
Journal:  Neurol Res       Date:  2008-05-21       Impact factor: 2.448

5.  Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats.

Authors:  Yoshiro Naito; Hisashi Sawada; Makiko Oboshi; Aya Fujii; Shinichi Hirotani; Toshihiro Iwasaku; Yoshitaka Okuhara; Akiyo Eguchi; Daisuke Morisawa; Mitsumasa Ohyanagi; Takeshi Tsujino; Tohru Masuyama
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.